

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)



(10) International Publication Number
WO 2022/072244 A1

(51) International Patent Classification:

A61K 31/713 (2006.01) A61K 39/395 (2006.01)
A61K 38/02 (2006.01) C12N 15/11 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/052001

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

24 September 2021 (24.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/087,095 02 October 2020 (02.10.2020) US

(71) Applicant: **IONIS PHARMACEUTICALS, INC.**
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **TSIMIKAS, Sotirios**; 2855 Gazelle Court,
Carlsbad, CA 92010 (US). **ALEXANDER, Veronica, J.**;
2855 Gazelle Court, Carlsbad, CA 92010 (US). **CROOKE,**
Stanley, T.; 2855 Gazelle Court, Carlsbad, CA 92010 (US).
GEARY, Richard, S.; 2855 Gazelle Court, Carlsbad, CA
92010 (US). **MONIA, Brett, P.**; 2855 Gazelle Court, Carls-
bad, CA 92010 (US).

(74) Agent: **LIU, Jing** et al.; Sheppard Mullin Richter & Hamp-
ton LLP, 650 Town Center Drive, 10th Floor, Costa Mesa,
CA 92626 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS FOR REDUCING APOCIII EXPRESSION

(57) Abstract: Provided herein are methods of administering ISIS 678354 for ameliorating Familial Chylomicronemia Syndrome (FCS), Familial Partial Lipodystrophy (FPL), Severe Hypertriglyceridemia (SHTG), reducing APOCIII RNA, or reducing APOCIII protein in a human subject in need thereof. In certain instances, methods are useful for ameliorating at least one symptom of FCS, FPL, or SHTG. Such symptoms of FCS include, but are not limited to, severe elevations in chylomicrons and extremely elevated TG levels (always reaching well above 1000 mg/dL and not infrequently rising as high as 10,000 mg/dL or more) with episodes of abdominal pain, physical fatigue, difficulty thinking, diarrhea, recurrent acute pancreatitis, eruptive cutaneous xanthomata, and hepatosplenomegaly.



WO 2022/072244 A1